Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis.
131I
Differentiated thyroid cancer
High risk
Intermediate risk
Meta-analysis
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
12
03
2021
accepted:
31
05
2021
pubmed:
19
6
2021
medline:
12
11
2021
entrez:
18
6
2021
Statut:
ppublish
Résumé
We performed a systematic review and a meta-analysis to investigate the successful ablation rate after radioiodine (RAI) administration in patients with differentiated thyroid cancer (DTC) at intermediate-high risk of recurrence. A comprehensive literature search of the PubMed, Scopus, and Web of Science databases was conducted according to the PRISMA statement. The final analysis included 9 studies accounting for 3103 patients at intermediate-high risk of recurrence. In these patients, the successful ablation rates ranged from 51 to 94% with a 71% pooled successful ablation and were higher in intermediate (72%) than in high (52%)-risk patients. Despite the rigorous inclusion standards, a significant heterogeneity among the evaluated studies was observed. Higher administered RAI activities are associated with a lower successful ablation rate in the whole population and in the subgroup of high-risk patients. Furthermore, pooled recurrence rate in intermediate-risk patients achieving successful ablation was only 2% during the subsequent 6.4-year follow-up while the pooled recurrence rate was 14% in patients who did not achieve a successful ablation. In a large sample of 3103 patients at intermediate-high risk of persistent/recurrent disease, 71% of patients achieved a successful ablation. In these intermediate-risk patients, the probability of subsequent recurrence is low and most recurrence occurred in those with already abnormal findings at the first control.
Identifiants
pubmed: 34142215
doi: 10.1007/s00259-021-05440-x
pii: 10.1007/s00259-021-05440-x
pmc: PMC8566414
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4437-4444Informations de copyright
© 2021. The Author(s).
Références
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.
doi: 10.1089/thy.2015.0020
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9.
doi: 10.1210/jc.2005-2838
Orosco RK, Hussain T, Noel JE, Chang DC, Dosiou C, Mittra E, et al. Radioactive iodine in differentiated thyroid cancer: a national database perspective. Endocr Relat Cancer. 2019;26:795–802.
doi: 10.1530/ERC-19-0292
Klain M, Ricard M, Leboulleux S, Baudin E, Schlumberger M. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S479–85.
doi: 10.1007/s00259-002-0810-9
Tuttle M, Morris LF, Haugen B, Shah J, Sosa JA, Rohren E, et al. Thyroid differentiated and anaplastic carcinoma. In: Amin MB, Edge SB, Greene F, Byrd D, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley J, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC cancer staging manual. Eighth ed. New York: Springer International Publishing; 2017.
Nascimento C, Borget I, Troalen F, Al Ghuzlan A, Deandreis D, Hartl D, et al. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur J Endocrinol. 2013;169:689–93.
doi: 10.1530/EJE-13-0386
Lamartina L, Durante C, Filetti S, Cooper DS. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab. 2015;100:1748–61.
doi: 10.1210/jc.2014-3882
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
doi: 10.1371/journal.pmed.1000097
Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag. 2014;3:123–8.
doi: 10.15171/ijhpm.2014.71
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
doi: 10.1002/sim.1186
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2008.
Ades AE, Lu G, Higgins JPT. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25:646.
doi: 10.1177/0272989X05282643
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
doi: 10.1136/bmj.315.7109.629
Caminha LS, Momesso DP, Vaisman F, Corbo R, Vaisman M. Long-term follow-up of patients with differentiated thyroid cancer who had negative 131I whole-body scan at first evaluation after treatment. Clin Nucl Med. 2013;38:765–9.
doi: 10.1097/RLU.0b013e31829f8c71
Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, Hong SJ, Shong YK, Kim WB. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Thyroid. 2014;24:820–5.
doi: 10.1089/thy.2013.0362
Verburg FA, Mäder U, Reiners C, Hänscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. J Clin Endocrinol Metab. 2014;99:4487–96.
doi: 10.1210/jc.2014-1631
Jeon MJ, Kim WG, Park WR, Han JM, Kim TY, Song DE, et al. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2013;170:23–30.
doi: 10.1530/EJE-13-0524
Rosario PW, Furtado Mde S, Mourão GF, Calsolari MR. Patients with papillary thyroid carcinoma at intermediate risk of recurrence according to American Thyroid Association criteria can be reclassified as low risk when the postoperative thyroglobulin is low. Thyroid. 2015;25:1243–8.
doi: 10.1089/thy.2015.0294
Jeong JH, Kong EJ, Jeong SY, Lee SW, Cho IH, Ah Chun K, et al. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer. Nucl Med Commun. 2017;38:228–33.
doi: 10.1097/MNM.0000000000000636
Llamas-Olier AE, Cuéllar DI, Buitrago G. Intermediate-risk papillary thyroid cancer: risk factors for early recurrence in patients with excellent response to initial therapy. Thyroid. 2018;28:1311–7.
doi: 10.1089/thy.2017.0578
Avram AM, Rosculet N, Esfandiari NH, Gauger PG, Miller BS, Cohen M, et al. Differentiated thyroid cancer outcomes after surgery and activity-adjusted 131I theragnostics. Clin Nucl Med. 2019;44:11–20.
doi: 10.1097/RLU.0000000000002321
Kim HK, Yoon JH, Cho JS, Kwon SY, Yoo SW, Kang HC. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer. Korean J Intern Med. 2020;35:1164–72.
doi: 10.3904/kjim.2018.173
Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Tumeurs de la ThyroïdeRefractaires Network for the Essai Stimulation Ablation Equivalence Trial, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.
doi: 10.1056/NEJMoa1108586
Alexander EK, Larsen PR. Radioiodine for thyroid cancer–is less more? N Engl J Med. 2012;366:1732–3.
doi: 10.1056/NEJMe1202172
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.
doi: 10.1056/NEJMoa1109589
Higgins JP. Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 2008;37:1158–60.
doi: 10.1093/ije/dyn204
IntHout J, Ioannidis JP, Borm GF, Goeman JJ. Small studies are more heterogeneous than large ones: a meta-meta-analysis. J Clin Epidemiol. 2015;68:860–9.
doi: 10.1016/j.jclinepi.2015.03.017
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;7414:557–60.
doi: 10.1136/bmj.327.7414.557
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database of Syst Rev. 2019. https://doi.org/10.1002/14651858.ED000142 .
doi: 10.1002/14651858.ED000142
Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723–9.
doi: 10.1210/jc.2005-0285